Merck Serono expands biopharmaceutical R&D facility to accelerate innovation

Merck Serono, the biopharmaceutical business of Merck, has announced the expansion of its R&D facility in Darmstadt, Germany.

The company is investing €65 million in a new laboratory building that will span more than 16,000 square metres and accommodate approximately 200 current employees whose focus will be accelerating innovation in research and development.

It was emphasised at the cornerstone laying ceremony, which took place in Darmstadt last week, that expansion and investment in innovation were the future driver of the company. In attendance were Belén Gairjo CEO Healthcare, and fellow Executive Board Member Kai Beckmann.

“When complete in 2017, we will offer our employees in research an open and modern environment that forester collaboration and innovation across disciplines,” says Beckmann. “With this building, we are sending out another signal that the Darmstadt site will continue to serve as a core R&D hub for Merck. In addition, the new laboratory building is an important element in the expansion of our global headquarters.”

The new building will unite different functions with R&D Discovery Technologies at the company, including molecular pharmacology, medicinal chemistry, computational chemistry, molecular interactions and biophysics, as well as protein engineering and antibody technologies, and protein and cell sciences.

The research building is due for completion by autumn 2017.

Image credit: Merck Serono